SubHero Banner

Zerbaxa®(ceftolozane/tazobactam) – Expanded indication

April 21, 2022 - The FDA approved Merck’s Zerbaxa (ceftolozane/tazobactam) for the treatment of the following infections caused by designated susceptible microorganisms in adult and pediatric patients (birth to < 18 years old): complicated intra-abdominal infections (cIAI) (used in combination with metronidazole), and complicated urinary tract infections (cUTI), including pyelonephritis.

Download PDF